Medical guideline

首页肿瘤学指南检索结果

检索结果

按发表年份

共搜索到26条与Evidence有关的结果

The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：其他 | 腹膜肿瘤

Japan Society of Gynecologic Oncology

The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely (1) Overview of the Guidelines (2) Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Recurrent Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (4) Borderline Epithelial Tumors of the Ovary (5) Malignant Germ Cell Tumors of the Ovary and (6) Malignant Sex Cord-stromal Tumors. Furthermore the Guidelines Comprise 5 Algorithms-namely (1) Initial Treatment for Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (2) Treatment for Recurrent Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Initial Treatment for Borderline Epithelial Ovarian Tumor (4) Treatment for Malignant Germ Cell Tumor and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer" (2) Involvement of Patients and General (male/female) Participants in Addition to Physicians Pharmacists and Nurses (3) Clinical Questions (CQs) in the PICO Format (4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System (5) Introduction of the Idea of a Body of Evidence (6) Categorization of References According to Research Design (7) Performance of Systematic Reviews and Meta-analysis for Three CQs and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 输卵管癌

Japan Society of Gynecologic Oncology

The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely (1) Overview of the Guidelines (2) Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Recurrent Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (4) Borderline Epithelial Tumors of the Ovary (5) Malignant Germ Cell Tumors of the Ovary and (6) Malignant Sex Cord-stromal Tumors. Furthermore the Guidelines Comprise 5 Algorithms-namely (1) Initial Treatment for Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (2) Treatment for Recurrent Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Initial Treatment for Borderline Epithelial Ovarian Tumor (4) Treatment for Malignant Germ Cell Tumor and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer" (2) Involvement of Patients and General (male/female) Participants in Addition to Physicians Pharmacists and Nurses (3) Clinical Questions (CQs) in the PICO Format (4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System (5) Introduction of the Idea of a Body of Evidence (6) Categorization of References According to Research Design (7) Performance of Systematic Reviews and Meta-analysis for Three CQs and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
The 2020 Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 卵巢肿瘤

Japan Society of Gynecologic Oncology

The Fifth Edition of the Japan Society of Gynecologic Oncology Guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer Was Published in 2020. the Guidelines Contain 6 Chapters-namely (1) Overview of the Guidelines (2) Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Recurrent Epithelial Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (4) Borderline Epithelial Tumors of the Ovary (5) Malignant Germ Cell Tumors of the Ovary and (6) Malignant Sex Cord-stromal Tumors. Furthermore the Guidelines Comprise 5 Algorithms-namely (1) Initial Treatment for Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (2) Treatment for Recurrent Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer (3) Initial Treatment for Borderline Epithelial Ovarian Tumor (4) Treatment for Malignant Germ Cell Tumor and (5) Treatment for Sex Cord-stromal Tumor. Major Changes in the New Edition Include the Following: (1) Revision of the Title to "guidelines for the Treatment of Ovarian Cancer Fallopian Tube Cancer and Primary Peritoneal Cancer" (2) Involvement of Patients and General (male/female) Participants in Addition to Physicians Pharmacists and Nurses (3) Clinical Questions (CQs) in the PICO Format (4) Change in the Expression of Grades of Recommendation and Level of Evidence in Accordance with the GRADE System (5) Introduction of the Idea of a Body of Evidence (6) Categorization of References According to Research Design (7) Performance of Systematic Reviews and Meta-analysis for Three CQs and (8) Voting for Each CQ/recommendation and Description of the Consensus.
指南简介 原文链接
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation Or Maintenance Systemic Therapy for Newly Diagnosed Stage Ii, Iii, Or Iv Epithelial Ovary, Fallopian Tube, Or Primary Peritoneal Carcinoma

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

Objective: to Provide Recommendations on Systemic Therapy Options in Consolidation Or Maintenance Therapy for Women with Newly Diagnosed Stage II III Or IV Epithelial Ovary Fallopian Tube Or Primary Peritoneal Carcinoma Including All Histological Types. Methods: Consistent with the Program in Evidence-based Program's Standardized Approach MEDLINE EMBASE PubMed Cochrane Library and PROSPERO (the International Prospective Register of Systematic Reviews) Databases and Four Relevant Conferences Were Systematically Searched. the Working Group Drafted Recommendations and Revised Them Based on the Comments from Internal and External Reviewers. Results: We Have One Recommendation for Consolidation Therapy and Eight Recommendations for Maintenance Therapy. Overall Consolidation Therapy with Chemotherapy Should Not Be Recommended in the Target Population. for Maintenance Therapy We Recommended Olaparib (Recommendation) Niraparib (Weak Recommendation) Veliparib (Weak Recommendation) and Bevacizumab (Weak Recommendation) for Certain Patients with Newly Diagnosed Stage III-IV Epithelial Ovarian Fallopian Tube Or Primary Peritoneal Carcinoma Respectively. We Do Not Recommend Some Agents as Maintenance Therapy in Four Recommendations. We Are Unable to Specify the Patient Population by Histological Types for Different Maintenance Therapy Recommendations. When New Evidence That Can Impact the Recommendations Is Available the Recommendations Will Be Updated as Soon as Possible.
指南简介 原文链接
Guidelines for Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection for Early Gastric Cancer (Second Edition)

2021年发布于 Digestive Endoscopy 33卷第1期 所属人体系统：消化 | 胃癌

Japan Gastroenterological Endoscopy Society Japanese Gastric Cancer Association

Early Gastric Cancer Endoscopic Mucosal Resection Endoscopic Submucosal Dissection Evidence-based Guidelines
指南简介 原文链接
ECO-SEOM-SEEO Safety Recommendations Guideline for Cancer Patients Receiving Intravenous Therapy

2020年发布于 Clinical and Translational Oncology 22卷第11期 所属人体系统：其他 | 治疗方案

Excellence and Quality in Oncology Spanish Society of Medical Oncology Spanish Society of Oncology Nursing

Cancer Therapy Clinical Practice Survey Decision Algorithm Evidence-based Recommendations Safety Venous Access.
指南简介 原文链接
Cancer Constipation: Clinical Summary of the ONS Guidelines™ for Opioid-Induced and Non-Opioid-Related Cancer Constipation

2020年发布于 Clinical journal of oncology nursing 24卷第6期 所属人体系统：其他 | 症状管理

Oncology Nursing Society

Acupuncture Constipation Evidence-based Guidelines Opioid-induced Constipation.
指南简介 原文链接
MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice from the Korean Society of Abdominal Radiology

2020年发布于 Korean J Radiol 21卷第7期 所属人体系统：消化 | 直肠癌

Korean Society of Abdominal Radiology

Adenocarcinoma CR Chemoradiation Chemoradiotherapy Evidence Guideline Magnetic Resonance Imaging Organ Preservation Recommendation Rectal Cancer Regression Remission Response Surveillance Wait and See Watch and Wait.
指南简介 原文链接
Recommendations for the Surveillance of Cancer-related Fatigue in Childhood, Adolescent, and Young Adult Cancer Survivors: a Report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

2020年发布于 Journal of cancer survivorship : research and practice 14卷第6期 所属人体系统：其他 | 症状管理

International Late Effects of Childhood Cancer Guideline Harmonization Group

Cancer-related Fatigue Childhood Adolescent and Young Adult Cancer Evidence-based Guidelines Late Effects Surveillance Survivors.
指南简介 原文链接
Guideline on Screening for Esophageal Adenocarcinoma in Patients with Chronic Gastroesophageal Reflux Disease

2020年 所属人体系统：消化 | 食管肿瘤

Canadian Task Force on Preventive Health Care

Clinical Practice Guidelines Evidence-based Medicine Family Medicine Primary Care Esophageal Adenocarcinoma
指南简介 原文链接
Clinical Practice Guidelines for Bladder Cancer 2019 Update by the Japanese Urological Association: Summary of the Revision

2020年发布于 Int J Urol 27卷第9期 所属人体系统：泌尿 | 膀胱肿瘤

Japanese Urological Association

Bladder Cancer Clinical Practice Guideline Diagnosis Evidenced-based Medicine Treatment.
指南简介 原文链接
Clinical Practice Guidelines for Bladder Cancer 2019 Update by the Japanese Urological Association: Summary of the Revision

2020年发布于 International Journal of Urology 27卷第9期 所属人体系统：泌尿 | 膀胱肿瘤

Japanese Urological Association

Bladder Cancer Clinical Practice Guideline Diagnosis Evidenced-based Medicine Treatment.
指南简介 原文链接
Multidisciplinary, Evidence-based Consensus Guidelines for Human Papillomavirus (HPV) Vaccination in High-risk Populations, Spain, 2016

2019年发布于 Euro Surveill 24卷第7期 所属人体系统：生殖 | 妇科肿瘤

无

HIV HIV Infection HPV MSM Evidence-based Medicine High-risk Populations Human Papillomavirus Infection Immunisation Men Who Have Sex with Men Vaccines
指南简介 原文链接
Evidence-based Recommendations for the Organization of Long-term Follow-up Care for Childhood and Adolescent Cancer Survivors: a Report from the PanCareSurFup Guidelines Working Group

2019年发布于 Journal of cancer survivorship : research and practice 13卷第5期 所属人体系统：其他 | 症状管理

PanCareSurFup Guidelines Working Group

Adolescent Child Evidence-based Guideline Follow-up Care Oncology Recommendations Survivor.
指南简介 原文链接
Reducing Pain in Children with Cancer: Methodology for the Development of a Clinical Practice Guideline

2019年发布于 Pediatric Blood and Cancer 66卷第6期 所属人体系统：其他 | 症状管理

Pain in Children with Cancer Guideline Development Panel

Clinical Practice Guideline Evidence-based Medicine Pain Pediatric Oncology Supportive Care
指南简介 原文链接
Guideline for the Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-line Chemotherapy

2018年发布于 Clin Oncol (R Coll Radiol) 30卷第10期 所属人体系统：呼吸 | 肺癌

Evidence-Based Care and by the Lung Cancer Disease Site Group

Chemotherapy Evidence-based Clinical Practice Guideline Irinotecan Platinum–etoposide Radiation Small Cell Lung Cancer
指南简介 原文链接
German S3 Guideline for Renal Cell Carcinoma : Presentation and Discussion of Essential Aspects for the Radiation Oncologist

2018年发布于 Strahlenther Onkol 194卷第1期 所属人体系统：泌尿 | 肾癌

无

Purpose: We Aim to Introduce and Discuss the Statements and Recommendations of the German S3 Guideline on Renal Cell Cancer for Daily Practice of Radiation Oncologists Methods: This Report Comprises Indication Treatment Decision Dose Prescription and Current Literature Including Treatment of Oligometastatic Disease Results: According to Different Stages of the Disease and the Structure of the Guideline We Focus on Five Treatment Situations and Recommendations for Decision Making: (1) Neo-/adjuvant Treatment Before Or after Nephrectomy: No Indication for Radiotherapy (2) Small Renal Mass: Stereotactic Ablative Radiotherapy Is Currently Seen as Experimental Option due to Small Patient Numbers Reported in the Literature However Local Tumor Control Achieved by SBRT Appears Favourable with >90% at 2 Years (3) Oligometastasis: Radiation Treatment with Higher Local Doses Or Stereotactic Treatment Is Possible after Interdisciplinary Discussion Indications for Palliative (4) and Symptomatic Treatment (5) Are Not Different Compared to Other Tumor Entities Conclusion: Currently There Is No Evidence-based Indication for Radiation Treatment in the Primary Setting (adjuvant/neoadjuvant Or Definitive) of Renal Cell Cancer in the Future Stereotactic Radiotherapy Should Have a Stronger Role in the Treatment of Medically Inoperable Patients with Primary Renal Cell Cancer and Especially in the Setting of Oligometastasis
指南简介 原文链接
European Evidence-based Guidelines on Pancreatic Cystic Neoplasms

2018年发布于 Gut 67卷第5期 所属人体系统：消化 | 胰腺肿瘤

European Study Group on Cystic Tumours of the Pancreas

Evidence-based Guidelines management pancreatic Cystic Neoplasms
指南简介 原文链接

人体系统

共搜索到26条 与Evidence有关的结果

2021年 发布于 Journal of Gynecologic Oncology 32卷 第2期 所属人体系统： 其他 | 腹膜肿瘤

Japan Society of Gynecologic Oncology

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 其他 | 腹膜肿瘤

Ontario Health (Cancer Care Ontario)

2021年 发布于 Journal of Gynecologic Oncology 32卷 第2期 所属人体系统： 生殖 | 输卵管癌

Japan Society of Gynecologic Oncology

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 输卵管癌

Ontario Health (Cancer Care Ontario)

2021年 发布于 Journal of Gynecologic Oncology 32卷 第2期 所属人体系统： 生殖 | 卵巢肿瘤

Japan Society of Gynecologic Oncology

2021年 发布于 Current Oncology 28卷 第2期 所属人体系统： 生殖 | 卵巢肿瘤

Ontario Health (Cancer Care Ontario)

2021年 发布于 Digestive Endoscopy 33卷 第1期 所属人体系统： 消化 | 胃癌

Japan Gastroenterological Endoscopy Society Japanese Gastric Cancer Association

2020年 发布于 Clinical and Translational Oncology 22卷 第11期 所属人体系统： 其他 | 治疗方案

Excellence and Quality in Oncology Spanish Society of Medical Oncology Spanish Society of Oncology Nursing

2020年 发布于 Clinical journal of oncology nursing 24卷 第6期 所属人体系统： 其他 | 症状管理

Oncology Nursing Society

2020年 发布于 Korean J Radiol 21卷 第7期 所属人体系统： 消化 | 直肠癌

Korean Society of Abdominal Radiology

2020年 发布于 Journal of cancer survivorship : research and practice 14卷 第6期 所属人体系统： 其他 | 症状管理

International Late Effects of Childhood Cancer Guideline Harmonization Group

2020年 所属人体系统： 消化 | 食管肿瘤

Canadian Task Force on Preventive Health Care

2020年 发布于 Int J Urol 27卷 第9期 所属人体系统： 泌尿 | 膀胱肿瘤

Japanese Urological Association

2020年 发布于 International Journal of Urology 27卷 第9期 所属人体系统： 泌尿 | 膀胱肿瘤

Japanese Urological Association

2019年 发布于 Euro Surveill 24卷 第7期 所属人体系统： 生殖 | 妇科肿瘤

无

2019年 发布于 Journal of cancer survivorship : research and practice 13卷 第5期 所属人体系统： 其他 | 症状管理

PanCareSurFup Guidelines Working Group

2019年 发布于 Pediatric Blood and Cancer 66卷 第6期 所属人体系统： 其他 | 症状管理

Pain in Children with Cancer Guideline Development Panel

2018年 发布于 Clin Oncol (R Coll Radiol) 30卷 第10期 所属人体系统： 呼吸 | 肺癌

Evidence-Based Care and by the Lung Cancer Disease Site Group

2018年 发布于 Strahlenther Onkol 194卷 第1期 所属人体系统： 泌尿 | 肾癌

无

2018年 发布于 Gut 67卷 第5期 所属人体系统： 消化 | 胰腺肿瘤

European Study Group on Cystic Tumours of the Pancreas

共搜索到26条与Evidence有关的结果

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：其他 | 腹膜肿瘤

2021年发布于 Current Oncology 28卷第2期 所属人体系统：其他 | 腹膜肿瘤

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 输卵管癌

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 输卵管癌

2021年发布于 Journal of Gynecologic Oncology 32卷第2期 所属人体系统：生殖 | 卵巢肿瘤

2021年发布于 Current Oncology 28卷第2期 所属人体系统：生殖 | 卵巢肿瘤

2021年发布于 Digestive Endoscopy 33卷第1期 所属人体系统：消化 | 胃癌

2020年发布于 Clinical and Translational Oncology 22卷第11期 所属人体系统：其他 | 治疗方案

2020年发布于 Clinical journal of oncology nursing 24卷第6期 所属人体系统：其他 | 症状管理

2020年发布于 Korean J Radiol 21卷第7期 所属人体系统：消化 | 直肠癌

2020年发布于 Journal of cancer survivorship : research and practice 14卷第6期 所属人体系统：其他 | 症状管理

2020年 所属人体系统：消化 | 食管肿瘤

2020年发布于 Int J Urol 27卷第9期 所属人体系统：泌尿 | 膀胱肿瘤

2020年发布于 International Journal of Urology 27卷第9期 所属人体系统：泌尿 | 膀胱肿瘤

2019年发布于 Euro Surveill 24卷第7期 所属人体系统：生殖 | 妇科肿瘤

2019年发布于 Journal of cancer survivorship : research and practice 13卷第5期 所属人体系统：其他 | 症状管理

2019年发布于 Pediatric Blood and Cancer 66卷第6期 所属人体系统：其他 | 症状管理

2018年发布于 Clin Oncol (R Coll Radiol) 30卷第10期 所属人体系统：呼吸 | 肺癌

2018年发布于 Strahlenther Onkol 194卷第1期 所属人体系统：泌尿 | 肾癌

2018年发布于 Gut 67卷第5期 所属人体系统：消化 | 胰腺肿瘤